Changes in plasma lipids predict pravastatin efficacy in secondary prevention

Area of Science:

• Cardiovascular Medicine
• Lipidomics
• Pharmacology

Background:

• Statins possess pleiotropic effects beyond lipid metabolism, but their impact on cardiovascular events is not fully understood.
• Investigating the relationship between statin-induced lipid changes and cardiovascular risk reduction is crucial for optimizing treatment.

Purpose of the Study:

• To characterize lipid profile alterations induced by pravastatin treatment.
• To determine the association between specific lipid changes and the reduction in future cardiovascular events.

Main Methods:

• Analysis of plasma lipids from 342 participants in the LIPID study subcohort (n=4991) at baseline and 1-year follow-up.
• Utilized linear and Cox regression to assess associations between lipid changes, treatment, and cardiovascular outcomes.
• Calculated relative risk reduction (RRR) for cardiovascular events.

Main Results:

• Pravastatin treatment altered 206 lipid species, with arachidonic acid species increasing and phosphatidylinositol species decreasing.
• The RRR for cardiovascular events decreased significantly after adjusting for LDL-cholesterol and further for the PI(36:2)/PC(38:4) ratio.
• The change in the PI(36:2)/PC(38:4) lipid ratio mediated 58% of the treatment effect, with no observed benefit in the highest quartile of change.

Conclusions:

• The change in the PI(36:2)/PC(38:4) lipid ratio is a significant predictor of pravastatin benefit, independent of LDL-cholesterol reduction.
• This lipid ratio shows potential as a biomarker for monitoring statin therapy efficacy in secondary cardiovascular prevention.